Find disease awareness content and relevant supporting materials

Migraine is a neurological disorder that manifests as a debilitating headache associated with altered sensory perception. The neuropeptide calcitonin gene-related peptide (CGRP) is now firmly established as a key player in migraine.

The neuropeptides calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) have emerged as mediators of migraine pathogenesis.

Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory neurons as well as in other cell types, such as motor neurons and neuroendocrine cells.

Purpose: To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies.

Aim: To systematically evaluate the safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies from the results of randomized controlled trials.

This 2022 EHF guideline update reviews the use of monoclonal antibodies targeting the CGRP pathway for migraine prevention. It incorporates new RCTs and real-world data to support the efficacy and safety of eptinezumab, erenumab, fremanezumab, and galcanezumab in both episodic and chronic migraine, with expert guidance on long-term management.

This AHS position statement affirms CGRP-targeting therapies as first-line options for migraine prevention. Backed by robust clinical trial and real-world evidence, monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and gepants (rimegepant, atogepant) show superior efficacy and tolerability compared to older treatments.

Migraine is a severe neurovascular disorder of which the pathophysiology is not yet fully understood. Besides the role of inflammatory mediators that interact with the trigeminovascular system, cyclic fluctuations in sex steroid hormones are involved in the sex dimorphism of migraine attacks.

Background: Several novel treatments targeting the calcitonin gene-related peptide pathway have been developed for migraine. We evaluated the efficacy of these medications, including atogepant, rimegepant, erenumab, eptinezumab, fremanezumab, and galcanezumab, for the prevention of migraine via network meta-analysis.

Latest insights and spotlight article